Pfizer prevails 10B bidding for Metsera, securing a deal to expand its obesity drug portfolio with innovative weight-loss treatments.

Pfizer Inc. acquires Metsera, Inc., beating Novo Nordisk, for up to $86.25/share. Click for my analysis of the deal and what ...

Metsera shares fell significantly as the firm accepted a $10 billion offer from Pfizer, ending its bidding war with Novo Nordisk. Despite the dip, Metsera shares have surged since Pfizer's initial ...

Stock futures are surging this morning after U.S. lawmakers passed a key procedural hurdle as part of an agreement that could ...

Shares of Novo Nordisk increased after the company withdrew its bid for U.S. weight loss drug maker Metsera, allowing Pfizer to secure a $10 billion deal. This move grants Pfizer entry into the ...

The start-up is making antivirals and cancer drugs for Big Pharma—and working to treat reproductive problems on its own ...

U.S. pharmaceutical giant Pfizer signed a deal to purchase development-stage obesity drugmaker Metsera Inc., winning a ...

Discover how DAOs revolutionize drug discovery through decentralized funding, transparency, and community governance.

The greater a company's earnings, the better its position will be to pay dividends. However, Pfizer's adjusted earnings per share (EPS) declined 18% year over year in Q3. That might seem to indicate ...

According to a new BioPharma Dive analysis, corporate-related funds such as Novo Holdings, Eli Lilly and Sanofi Ventures have ...

Most days, Mary Jane Winsted and her adult daughter with a disability only have one meal a day. That's all the 54-year-old can afford with the $298 she gets monthly from the Supplemental Nutrition ...

Several states are trying different strategies to address the funding lapse in food benefits distributed under the Supplemental Nutrition Assistance Program during the government shutdown.